Drug Profile

NS 229 - Nippon Shinyaku

Alternative Names: NS-221

Latest Information Update: 01 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nippon Shinyaku; NS Pharma
Class Anti-inflammatories; Antiepileptic drugs; Neuroprotectants; Small molecules
Mechanism of Action Janus kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Churg-Strauss syndrome
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Churg-Strauss syndrome

Most Recent Events

24 Jan 2024 NS 229 is still in phase I/II trial for Churg-Strauss-syndrome (NS pharma pipeline, January 2024)
22 Jan 2024 NS 229 receives Orphan Drug status for Churg-Strauss syndrome in European Union
28 Dec 2023 No recent reports of development identified for phase-I development in Inflammation in Japan (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com